Clinical Trials

Carcinoma, Hepatocellular

NCT06138496 2026-04-21

Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC

Phase 2 Completed

39 enrolled

Carcinoma, Renal Cell

NCT04393350 2026-04-20

Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma

18 enrolled 12 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT05775159 2026-04-17

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

294 enrolled

Biliary Tract Neoplasms, Carcinoma, Hepatocellular

NCT07405164 2026-04-17

MK-6482-043

Phase 3 Recruiting

450 enrolled

Phase NA Not yet recruiting

Carcinoma, Renal Cell, von Hippel-Lindau Disease

NCT07535840 2026-04-17

A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular Carcinoma

25 enrolled

Phase 3 Not yet recruiting

Carcinoma, Hepatocellular

NCT07537946 2026-04-17

Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer

400 enrolled

Carcinoma, Hepatocellular, Neoplasm Metastasis

NCT05064280 2026-04-16

Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases

104 enrolled

CNS

Brain Neoplasms, Neoplasms

NCT06669572 2026-04-15

Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment

35 enrolled

Tumor-Agnostic

Carcinoma, Squamous Cell

NCT07530445 2026-04-15

Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer

40 enrolled

Phase 3 Active not recruiting

Biliary Tract Neoplasms

NCT04164199 2026-04-14

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

404 enrolled

Advanced Malignancies

NCT06880523 2026-04-14

SLIDE-HCC

140 enrolled

Other hematologic neoplasm

Carcinoma, Hepatocellular

NCT03486873 2026-04-13

MK-3475-587

Phase 3 Recruiting

3,500 enrolled

Hematologic Neoplasms

NCT04938817 2026-04-13

KEYNOTE-B98

110 enrolled

Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Small Cell Lung Carcinoma

NCT04745988 2026-04-09

An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric Cancer

43 enrolled

Stomach Neoplasms

NCT05696548 2026-04-09

Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)

51 enrolled

EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

NCT06253494 2026-04-09

Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer

60 enrolled

Endometrial Neoplasms

NCT07518706 2026-04-09

Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin

60 enrolled

Phase 1/2 Active not recruiting

Carcinoma, Hepatocellular

NCT04305054 2026-04-08

KEYMAKER-U02

315 enrolled

Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT04869137 2026-04-08

Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma

26 enrolled 9 charts

Dermatologic

Skin Neoplasms, Carcinoma, Merkel Cell

NCT05327686 2026-04-08

SAMURAI

240 enrolled

Phase 3 Active not recruiting

Carcinoma, Renal Cell

NCT05301842 2026-04-07

EMERALD-3

760 enrolled

Phase 3 Active not recruiting

Carcinoma, Hepatocellular, Liver Neoplasms

NCT04039607 2026-04-06

CheckMate 9DW

732 enrolled 2 FDA

Carcinoma, Hepatocellular

NCT05286437 2026-04-06

LaPemERLA

40 enrolled

Breast

Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer

NCT07096609 2026-04-03

LONGIST

48 enrolled

Sarcoma

GIST

NCT07290894 2026-04-02

MITO VULVA-01

80 enrolled

Vulvar Neoplasms

NCT06110793 2026-03-30

A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer

49 enrolled

Breast

Breast Neoplasms

NCT04199104 2026-03-27

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)

Phase 3 Completed

511 enrolled 20 charts

Squamous Cell Carcinoma of Head and Neck

NCT07495579 2026-03-27

REVIVE

146 enrolled

Carcinoma, Hepatocellular

NCT05024214 2026-03-25

Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

GastrointestinalGenitourinaryThoracic

170 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular

NCT06858813 2026-03-25

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)

Phase 1 Recruiting

232 enrolled

Liver Neoplasms

NCT07493668 2026-03-25

FLEX-HCC

80 enrolled

Phase 1/2 Active not recruiting

Carcinoma, Hepatocellular

NCT04008797 2026-03-24

A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

301 enrolled

GastrointestinalGynecologic

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05733715 2026-03-24

Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma

Phase EARLY_PHASE1 Recruiting

30 enrolled

Carcinoma, Renal Cell

NCT05319730 2026-03-20

MK-3475-06B

230 enrolled

827 enrolled 34 charts 2 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT03517449 2026-03-19

MK-3475-775

Phase 3 Completed

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT03950609 2026-03-19

Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors

36 enrolled

EndocrineNET

Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1

NCT06036836 2026-03-19

MK-4280A-010

Phase 2 Completed

163 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT04977453 2026-03-17

Keynote B59

317 enrolled

GenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Neoplasm Metastasis

NCT05746208 2026-03-17

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

29 enrolled

EndocrineNET

Neuroendocrine Tumors

NCT07092514 2026-03-17

Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)

34 enrolled

Phase 3 Not yet recruiting

Thyroid Neoplasms

NCT07475026 2026-03-16

A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence

198 enrolled

Carcinoma, Hepatocellular

NCT04300556 2026-03-13

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

BreastGynecologicThoracic

182 enrolled

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05523323 2026-03-13

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension

Phase 3 Completed

112 enrolled 16 charts

Squamous Cell Carcinoma of Head and Neck

NCT05824468 2026-03-10

Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer

30 enrolled

Uterine Cervical Neoplasms

NCT05824481 2026-03-10

Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer

32 enrolled

Endometrial Neoplasms

NCT07460206 2026-03-10

PRELUDE

108 enrolled

Carcinoma, Renal Cell

NCT06859684 2026-03-09

HAIC-quad

25 enrolled

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

NCT03573960 2026-03-06

A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer

Phase 4 Completed

50 enrolled